Effects of doxofylline as an adjuvant on severe exacerbation and long ‐term prognosis for COPD with different clinical subtypes

ConclusionsAs an adjuvant drug, doxofylline has a good therapeutic effect on patients with the neutrophilic and eosinophilic clinical subtypes of COPD. It can reduce the incidence of severe exacerbation, the use of glucocorticoids, and inflammatory reactions in the long term (when used for a minimum of 3 months).

Source: The Clinical Respiratory Journal - August 11, 2023 Category: Respiratory Medicine Authors: Mei ‐Feng Chen, Wei He, De‐Sheng Huang, Hui Jia, Zhao‐Shuang Zhong, Nan Li, Shan‐Shan Li, Shu‐Yue Xia Tags: ORIGINAL ARTICLE Source Type: research